David R. Lally, MD, discusses promising results from the ARCHER trial on ANX007 for age-related macular degeneration, emphasizing the need for vision-preserving treatments.
David R. Lally, MD
Advertisement
Articles by David R. Lally, MD
Advertisement
Latest Updated Articles
Q&A: The ARCHER trial and the importance of continued GA researchPublished: October 13th 2025 | Updated:
Advertisement
Advertisement
Trending on Modern Retina
1
EyePoint receives second consecutive positive recommendation from DSMC
2
AGC Biologics to manufacture AAVantgarde’s dual-vector gene therapies, AVB-039 and AAVB-081
3
FLORetina 2025: Industry advances front and center at FLORetina Congress
4
Eichenbaum Acorns: Inside the mindset of an early adopter with Jordan M. Graff, MD, FACS
5
